<DOC>
	<DOCNO>NCT01255358</DOCNO>
	<brief_summary>Multi-centre , single arm , open label , 6 month , phase II study evaluate effect Ery-Dex improve Central Nervous System ( CNS ) symptoms patient Ataxia Teleangiectasia ( AT ) . The study consist screen period ( max duration 30 day ) treatment period ( duration 6 month ) .</brief_summary>
	<brief_title>Intra-Erythrocyte Dexamethasone Sodium Phosphate Ataxia Teleangiectasia Patients</brief_title>
	<detailed_description>The study aim evaluate improvement CNS symptom measure International Co-operative Ataxia Rating Scale ( ICARS ) patient AT , period treatment Ery-Dex ( dexamethasone sodium phosphate ex vivo encapsulate human autologous erythrocyte ) .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>neurological sign AT patient autonomous gait help support proven molecular diagnosis AT Males female age &gt; 3 year Body weight &gt; 15 kg Plasma level Lymphocytes CD4+/mm3 &gt; 500 ( patient age 36 year ) &gt; 200 ( old 6 year ) Current previous neoplastic disease History severe impairment immunological system Chronic condition represent contraindication use steroid drug Non compliance study request Any previous steroid assumption within 30 day start EryDex</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Ataxia Teleangiectasia</keyword>
	<keyword>AT</keyword>
	<keyword>Ery-Dex</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Dexamethasone sodium phosphate</keyword>
</DOC>